Current Neurology and Neuroscience Reports

, Volume 6, Issue 2, pp 136–143

Neurofibromatosis type 1: New insights into neurocognitive issues

  • Maria T. Acosta
  • Gerard A. Gioia
  • Alcino J. Silva
Article

Abstract

Neurofibromatosis type 1 (NF1) is a neurocutaneous disorder with a prevalence of approximately 1 in 3500 people. Academic difficulties and school failure are the most common reported complication of NF1 in childhood and are present in 40% to 60% of the cases. They are often the most significant cause of lifetime morbidity in this population. Recent advances in the recognition and characterization of the cognitive phenotype in NF1 patients have provided a better understanding of the neuropsychologic deficits that account for the impairments in cognitive performance and social interaction. Additionally, recent advances in the understanding of molecular and cellular mechanisms underlying the cognitive deficits in NF1, as well as developments in neuroimaging and molecular genetic techniques are starting to yield a global and integrative picture of the molecular, cellular, and brain system processes affected by this condition. This review focuses on these advances, as well as recent preclinical studies that point towards potential pharmacologic interventions for NF1 patients.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Castle B, Baser ME, Huson SM, et al.: Evaluation of genotype-phenotype correlations in neurofibromatosis type 1. J Med Genet 2003, 40:e109.PubMedCrossRefGoogle Scholar
  2. 2.
    Huson SM: Recent developments in the diagnosis and management of neurofibromatosis. Arch Dis Child 1989, 64:745–749.PubMedGoogle Scholar
  3. 3.
    North K, Joy P, Yuille D, et al.: Cognitive function and academic performance in children with neurofibromatosis type 1. Dev Med Child Neurol 1995, 37:427–436.PubMedCrossRefGoogle Scholar
  4. 4.
    Ozonoff S: Cognitive impairment in neurofibromatosis type 1. Am J Med Genet 1999, 89:45–52.PubMedCrossRefGoogle Scholar
  5. 5.
    North KN, Riccardi V, Samango-Sprouse C, et al.: Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force. Neurology 1997, 48:1121–1127.PubMedGoogle Scholar
  6. 6.
    Hyman SL, Shores A, North KN: The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 2005, 65:1037–1044. Extensive neuropsychologic evaluation in children with NF1 compared with sibling controls.PubMedCrossRefGoogle Scholar
  7. 7.
    Ballester R, Marchuk D, Boguski M, et al.: The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IR A proteins. Cell 1990, 63:851–859.PubMedCrossRefGoogle Scholar
  8. 8.
    Martin GA, Viskochil D, Bollag G, et al.: The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990, 63:843–849.PubMedCrossRefGoogle Scholar
  9. 9.
    Xu GF, Lin B, Tanaka K, et al.: The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 1990, 63:835–841.PubMedCrossRefGoogle Scholar
  10. 10.
    Guo HF, Tong J, Hannan F, et al.: A neurofibromatosis-1-regulated pathway is required for learning in Drosophila. Nature 2000, 403:895–898.PubMedCrossRefGoogle Scholar
  11. 11.
    Xu H, Gutmann DH: Mutations in the GAP-related domain impair the ability of neurofibromin to associate with microtubules. Brain Res 1997, 759:149–152.PubMedCrossRefGoogle Scholar
  12. 12.
    Bernards A, Snijders AJ, Hannigan GE, et al.: Mouse neuro-fibromatosis type 1 cDNA sequence reveals high degree of conservation of both coding and non-coding mRNA segments. Hum Mol Genet 1993, 2:645–650.PubMedCrossRefGoogle Scholar
  13. 13.
    Costa RM, Silva AJ: Mouse models of neurofibromatosis type I: bridging the GAP. Trends Mol Med 2003, 9:19–23.PubMedCrossRefGoogle Scholar
  14. 14.
    Costa RM, Silva AJ: Molecular and cellular mechanisms underlying the cognitive deficits associated with neurobromatosis 1. J Child Neurol 2002, 17:622–626.PubMedCrossRefGoogle Scholar
  15. 15.
    Hyman SL, Gill DS, Shores EA, et al.: Natural history of cognitive deficits and their relationship to MRI T2-hyperintensities in NF1. Neurology 2003, 60:1139–1145.PubMedGoogle Scholar
  16. 16.
    Cutting LE, Koth CW, Denckla MB: How children with neurofibromatosis type 1 differ from "typical" learning disabled clinic attenders: nonverbal learning disabilities revisited. Dev Neuropsychol 2000, 17:29–47.PubMedCrossRefGoogle Scholar
  17. 17.
    Huson SM, Harper PS, Compston DA: Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 1988, 111(Pt 6):1355–1381.PubMedCrossRefGoogle Scholar
  18. 18.
    North K, Joy P, Yuille D, et al.: Specific learning disability in children with neurofibromatosis type 1: significance of MRI abnormalities. Neurology 1994, 44:878–883.PubMedGoogle Scholar
  19. 19.
    North K: Neurofibromatosis type 1. Am J Med Genet 2000, 97:119–127.PubMedCrossRefGoogle Scholar
  20. 20.
    Joy P, Roberts C, North K, de Silva M: Neuropsychological function and MRI abnormalities in neurofibromatosis type 1. Dev Med Child Neurol 1995, 37:906–914.PubMedCrossRefGoogle Scholar
  21. 21.
    Moore BD III, Ater JL, Needle MN, et al.: Neuropsychological profile of children with neurofibromatosis, brain tumor, or both. J Child Neurol 1994, 9:368–377.PubMedGoogle Scholar
  22. 22.
    Rosser TL, Packer RJ: Neurocognitive dysfunction in children with neurofibromatosis type 1. Curr Neurol Neurosci Rep 2003, 3:129–136.PubMedCrossRefGoogle Scholar
  23. 23.
    Eliason MJ: Neurofibromatosis: implications for learning and behavior. J Dev Behav Pediatr 1986, 7:175–179.PubMedCrossRefGoogle Scholar
  24. 24.
    Kayl AE, Moore BD III, Slopis JM, et al.: Quantitative morphology of the corpus callosum in children with neurofibromatosis and attention-deficit hyperactivity disorder. J Child Neurol 2000, 15:90–96.PubMedCrossRefGoogle Scholar
  25. 25.
    Koth CW, Cutting LE, Denckla MB: The association of neurofibromatosis type 1 and attention deficit hyperactivity disorder. Neuropsychol Dev Cogn C Child Neuropsychol 2000, 6:185–194.CrossRefGoogle Scholar
  26. 26.
    Mautner VF, Kluwe L, Thakker SD, Leark RA: Treatment of ADHD in neurofibromatosis type 1. Dev Med Child Neurol 2002, 44:164–170.PubMedCrossRefGoogle Scholar
  27. 27.
    Gioia GA, Isquith PK, Kenworthy L, Barton RM: Profiles of everyday executive function in acquired and developmental disorders. Neuropsychol Dev Cogn C Child Neuropsychol 2002, 8:121–137.CrossRefGoogle Scholar
  28. 28.
    Pennington PF, Bennetto L, McAleer OK, Roberts RL: Executive functions and working memory: theoretical and measurements issues. In Attention, Memory and Executive Function. Edited by Lyon GR, Krasnegor NA. Baltimore: Paul H. Brookes Publishing; 1996.Google Scholar
  29. 29.
    Barkley RA: Genetics of childhood disorders: XVII. ADHD, Part 1: The executive functions and ADHD. J Am Acad Child Adolesc Psychiatry 2000, 39:1064–1068.PubMedCrossRefGoogle Scholar
  30. 30.
    Barkley RA: ADHD and the Nature of Self-Control. New York: Guilford Press; 1997.Google Scholar
  31. 31.
    Barkley RA: Linkages between attention and executive function. In Attention, Memory and Executive Function. Edited by Lyon GR, Krasnegor NA. Baltimore: Paul H. Brookes; 1996.Google Scholar
  32. 32.
    Gioia GA, Isquith PK: Executive function and ADHD: exploration through children’s everyday behaviors. Clin Neuropsychol Assessment 2001, 2:61–64.Google Scholar
  33. 33.
    Ferner RE, Hughes RA, Weinman J: Intellectual impairment in neurofibromatosis 1. J Neurol Sci 1996, 138:125–133.PubMedCrossRefGoogle Scholar
  34. 34.
    Hofman KJ, Harris EL, Bryan RN, Denckla MB: Neuro-fibromatosis type 1: the cognitive phenotype. J Pediatr 1994, 124:S1-S8.PubMedCrossRefGoogle Scholar
  35. 35.
    Mazzocco MM: Math learning disability and math LD subtypes: evidence from studies of Turner syndrome, fragile X syndrome, and neurofibromatosis type 1. J Learn Disabil 2001, 34:520–533.PubMedCrossRefGoogle Scholar
  36. 36.
    Zoller ME, Rembeck B, Backman L: Neuropsychological deficits in adults with neurofibromatosis type 1. Acta Neurol Scand 1997, 95:225–232.PubMedCrossRefGoogle Scholar
  37. 37.
    Eliason MJ: Neuropsychological patterns: neurofibromatosis compared to developmental learning disorders. Neurofibromatosis 1988, 1:17–25.PubMedGoogle Scholar
  38. 38.
    Daston MM, Ratner N: Neurofibromin, a predominantly neuronal GTPase activating protein in the adult, is ubiquitously expressed during development. Dev Dyn 1992, 195:216–226.PubMedGoogle Scholar
  39. 39.
    Daston MM, Scrable H, Nordlund M, et al.: The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron 1992, 8:415–428.PubMedCrossRefGoogle Scholar
  40. 40.
    Tong J, Hannan F, Zhu Y, et al.: Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat Neurosci 2002, 5:95–96.PubMedCrossRefGoogle Scholar
  41. 41.
    Li C, Cheng Y, Gutmann DA, Mangoura D: Differential localization of the neurofibromatosis 1 (NF1) gene product, neurofibromin, with the F-actin or microtubule cytoskeleton during differentiation of telencephalic neurons. Brain Res Dev Brain Res 2001, 130:231–248.PubMedCrossRefGoogle Scholar
  42. 42.
    Brannan CI, Perkins AS, Vogel KS, et al.: Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 1994, 8:1019–1029.PubMedCrossRefGoogle Scholar
  43. 43.
    Jacks T, Shih TS, Schmitt EM, et al.: Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 1994, 7:353–361.PubMedCrossRefGoogle Scholar
  44. 44.
    Costa RM, Federov NB, Kogan JH, et al.: Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 2002, 415:526–530. Presentation of biologic mechanisms implicated in learning deficits in a mouse model of NF1.PubMedCrossRefGoogle Scholar
  45. 45.
    Silva AJ, Elgersma Y, Costa RM: Molecular and cellular mechanisms of cognitive function: implications for psychiatric disorders. Biol Psychiatry 2000, 47:200–209.PubMedCrossRefGoogle Scholar
  46. 46.
    Weeber EJ, Levenson JM, Sweatt JD: Molecular genetics of human cognition. Mol Interv 2002, 2:376–391.PubMedCrossRefGoogle Scholar
  47. 47.
    Costa RM, Yang T, Huynh DP, et al.: Learning deficits, but normal development and tumor predisposition, in mice lacking exon 23a of Nf1. Nat Genet 2001, 27:399–405.PubMedCrossRefGoogle Scholar
  48. 48.
    Silva AJ, Frankland PW, Marowitz Z, et al.: A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat Genet 1997, 15:281–284.PubMedCrossRefGoogle Scholar
  49. 49.
    Mazieres J, Pradines A, Favre G: Perspectives on farnesyl transferase inhibitors in cancer therapy. Cancer Lett 2004, 206:159–167.PubMedCrossRefGoogle Scholar
  50. 50.
    Li W, Cui Y, Kushner SA, et al.: The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 2005, 15:1961–1967. Use of lovastatin in a mouse model of NF1 to revert neurocognitive deficits.PubMedCrossRefGoogle Scholar
  51. 51.
    Kwiterovich PO Jr: Safety and efficacy of treatment of children and adolescents with elevated low density lipoprotein levels with a step two diet or with lovastatin. Nutr Metab Cardiovasc Dis 2001, 11(Suppl 5):30–34.PubMedGoogle Scholar
  52. 52.
    Stein EA, Illingworth DR, Kwiterovich PO Jr, et al.: Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 1999, 281:137–144.PubMedCrossRefGoogle Scholar
  53. 53.
    Lambert M, Lupien PJ, Gagne C, et al.: Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics 1996, 97:619–628.PubMedGoogle Scholar
  54. 54.
    Kleschevnikov AM, Belichenko PV, Villar AJ, et al.: Hippocampal long-term potentiation suppressed by increased inhibition in the ts65dn mouse, a genetic model of Down syndrome. J Neurosci 2004, 24:8153–8160.PubMedCrossRefGoogle Scholar
  55. 55.
    Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988, 45:575–578.Google Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  • Maria T. Acosta
    • 1
  • Gerard A. Gioia
  • Alcino J. Silva
  1. 1.Department of NeurologyChildren’s National Medical CenterWashingtonUSA

Personalised recommendations